



Present



# LUNG CANCER

**17<sup>th</sup>**

**JUNE**  
SATURDAY

**2023**

**17 : 00**  
**20 : 30**

**Venue: ITC Grand Central, Mumbai**

**Hybrid Meeting**

**INTERNATIONAL SPEAKER**



**DR. JESSICA LIN**

**Medical Oncologist,  
Assistant Professor of Medicine, Harvard Medical School,**


**Attending Physician, Center for Thoracic Cancers,  
Massachusetts General Hospital,**

**Attending Physician, Henri 7 Belinda Termeer Center for  
Targeted Therapies, Massachusetts General Hospital, USA**

[Click here for disclaimer](#)

[Click link below or scan QR for registration](#)

<https://www.riverroute.in/pfizeroncosummit>



[Click here to join the meeting](#)

**Meeting ID: 290 348 741 458**

**Passcode: JnQZy5**



**Pfizer Products India Private Limited**

The Capital, B Wing, 1802, Plot No. C-70, G Block, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051, India.

Full Prescribing / Product Information available on request

For the use only of Registered Medical Practitioners or a Hospital or a Laboratory

08/06/2023 EM-IND-OABL-0010



Present



# LUNG CANCER

SATURDAY, 17<sup>TH</sup> JUNE, 2023  
17:00 - 20:30

## ABOUT DR. JESSICA LIN

Dr. Lin is an attending physician in the Center for Thoracic Cancers and Henri and Belinda Termeer Center for Targeted Therapies at Massachusetts General Hospital. She is an Assistant Professor of Medicine at Harvard Medical School.


Dr. Lin earned her bachelor's degree in Biochemistry at Harvard College and medical degree from Harvard Medical School. She completed her internship and residency in internal medicine at Brigham and Women's Hospital, serving as Chief Medical Resident at Brigham and Women's Faulkner Hospital. She subsequently trained in the Dana-Farber/MGH joint hematology/oncology fellowship program.

Dr. Lin's major research interests include studying driver oncogene alterations in non-small cell lung cancer and development of resistance to targeted therapies. She leads clinical trials of novel targeted therapy and immunotherapy agents in lung cancer. Her work has been recognized by awards and grants from organizations such as the Conquer Cancer Foundation/American Society of Clinical Oncology, International Association for the Study of Lung Cancer and prIME Oncology.

[Click here for disclaimer](#)

[Click link below or scan QR for registration](#)

<https://www.riverroute.in/pfizeroncosummit>



[Click here to join the meeting](#)

Meeting ID: 290 348 741 458

Passcode: JnQZy5



Pfizer Products India Private Limited

The Capital, B Wing, 1802, Plot No. C-70, G Block, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051, India.

Full Prescribing / Product Information available on request

For the use only of Registered Medical Practitioners or a Hospital or a Laboratory

EM-IND-OABL-0010



Present



# LUNG CANCER

SATURDAY, 17<sup>TH</sup> JUNE, 2023  
17:00 - 20:30

## SCIENTIFIC PROGRAM


### Program Moderator - Dr. Vijay Patil

17:00 - 17:05	Welcome and Opening remarks <b>Dr. Pankaj Gupta</b> Country Medical Director, Pfizer India
17:05 - 17:20	Precision Oncology for NSCLC in 2023 <b>Speaker: Dr. Aditya Murali</b>
17:20 - 17:40	Evolution of 1L Landscape in ALK+ NSCLC <b>Speaker: Dr. Jessica Lin</b>
17:40 - 18:00	Managing CNS disease in ALK+ NSCLC <b>Speaker: Dr. Vijay Patil</b>
18:00 - 18:25	Debate: Most efficacious drug should be used upfront for ALK+ NSCLC <b>For: Dr. Senthil Rajappa</b> <b>Against: Dr. Amit Rauthan</b> <b>Moderator: Dr. Jessica Lin</b>
18:25 - 19:00	Case based Panel discussion-ALK+NSCLC <b>Moderator: Dr. Senthil Rajappa</b> <b>Panelists: Dr. Jessica Lin,</b> <b>Dr. Amit Rauthan, Dr. Vijay Patil,</b> <b>Dr. Aditya Murali, Dr. Shailesh Bondarde</b>

[Click here for disclaimer](#)

Click link below or scan QR for registration

<https://www.riverroute.in/pfizeroncosummit>



[Click here to join the meeting](#)

Meeting ID: 290 348 741 458

Passcode: JnQZy5



Pfizer Products India Private Limited

The Capital, B Wing, 1802, Plot No. C-70, G Block, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051, India.

Full Prescribing / Product Information available on request

For the use only of Registered Medical Practitioners or a Hospital or a Laboratory

EM-IND-OABL-0010



Present



# LUNG CANCER

SATURDAY, 17<sup>TH</sup> JUNE, 2023  
17:00 - 20:30


## SCIENTIFIC PROGRAM

<b>19:00 - 19:15</b>	<b>BREAK</b>
19:15 - 19:20	Context Setting <b>Dr. Vijay Patil</b>
19:20 - 19:55	Case Based Panel Discussion EGFR+ NSCLC <b>Moderator: Dr. Mohit Agarwal</b> <b>Panelists: Dr. Jessica Lin, Dr. G. Sadashivudu, Dr. Rakesh Taran, Dr. Vaibhav Choudhary, Dr. Rohit Pai</b>
19:55 - 20:15	ASCO updates <b>Speaker: Dr. Vaibhav Choudhary</b>
20:15 - 20:20	Closing Remarks <b>Dr. Vijay Patil</b>
	Vote of Thanks <b>Dr. Shashank Srinivasan</b> Medical Advisor Oncology, Pfizer India

[Click here for disclaimer](#)

Click link below or scan QR for registration

<https://www.riverroute.in/pfizeroncosummit>



[Click here to join the meeting](#)

Meeting ID: 290 348 741 458

Passcode: JnQZy5



Pfizer Products India Private Limited

The Capital, B Wing, 1802, Plot No. C-70, G Block, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051, India.

Full Prescribing / Product Information available on request

For the use only of Registered Medical Practitioners or a Hospital or a Laboratory

EM-IND-OABL-0010